Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Review Of Reviews: Drug Review Profiles 2013

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.


Related Content

The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival
Breo Inverts Traditional Path To COPD Indication For LABA Combinations
Eliquis Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial
“Marginal” Mortality Benefit Belongs In Eliquis’ Label, But Not The Indication Statement, FDA Says
Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design
A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In Fulyzaq Review
Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem
Randomization Required: Liver Signal Necessitated Kadcyla Trial With Control Arm
Aubagio Approval Reflects FDA’s Evolving View On Multiple Sclerosis Drugs
FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts